Pfizer Inc. and BioNTech could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.
The vaccine's efficacy was found to be consistent across different ages and ethnicities — a promising sign given the disease has disproportionately hurt the elderly and certain groups including Black people.
The U.S. Food and Drug Administration could grant emergency-use by the middle of December, BioNTech Chief Executive Ugur Sahin said. Conditional approval in the European Union could be secured in the second half of December, he added.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.